gem3psca
mAbexperimentalMulti-specific
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 15, 2019 (NCT03927573)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Prostate stem cell antigenINHIBITOR
PSCA inhibitor
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03927573 | Phase 1 | Apr 15, 2019 | GCP-Service International Ltd. & Co. KG, GEMoaB Monoclonals GmbH, University of Applied Sciences Würzburg-Schweinfurt |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GCP-Service International Ltd. & Co. KG | For profit | 1 | 0 | 1 | 2019 |
| GEMoaB Monoclonals GmbH | For profit | 1 | 1 | 1 | 2019 |
| University of Applied Sciences Würzburg-Schweinfurt | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1